A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of Brexpiprazole (1 - 3 mg/day) as Monotherapy or as Combination Therapy in the Treatment of Adults with Post-traumatic Stress Disorder
Primary: To evaluate the efficacy of brexpiprazole as monotherapy or as combination treatment with Zoloft (sertraline) in adult subjects with PTSD.
Secondary: To evaluate the safety and tolerability of brexpiprazole 1 to 3 mg/day as monotherapy or as combination treatment with Zoloft (sertraline) in adult subjects with PTSD.
Free trial related exams and medications.
| Condition | Post-Traumatic Stress Disorders, Post-Traumatic Stress Disorders, Post-Traumatic Stress Disorders |
|---|---|
| Clinical Study Identifier | TX10865 |
| Sponsor | Otsuka |
| Last Modified on | 23 November 2020 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.